Cisplatin, methotrexate and mitoxantrone in patients with metastatic or advanced urothelial cancer

Acta Oncologica

Volumn 37, Issue 1, 1998, Pages 110-112

  Andersen, Lisbeth J ^a,c   Sengeløv, Lisa ^b   Kamby, Claus ^b   Von Der Maase, Hans ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; METHOTREXATE; MITOXANTRONE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; SURVIVAL TIME; UROGENITAL TRACT TUMOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MITOXANTRONE; TREATMENT OUTCOME; UROLOGIC NEOPLASMS;

EID: 0031917683     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698423276     Document Type: Article

References (21)

1. Sternberg CN, Yagoda A. Scher III, et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 1985: 133: 403-7.
2. Sternberg CN, Yagoda A. Scher III, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988; 139: 461- 9.
3. Tannock I, Giospodarowicz M, Connolly J, Jewett M. MVAC (methotrexate. vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 1989; 142: 289- 92.
4. Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990; 8: 1050- 5.
5. Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma. a cooperative study. J Clin Oncol 1992; 10: 1066- 73.
6. Sternberg CN. The treatment of advanced bladder cancer. Ann Oncol 1995; 6: 113- 26.
7. Steineck G, Wijkström H. Borghede G. Cytostatikaterapi vid urinblasecaneer. läkartid 1994; 91: 397- 404.
8. Saxman SB, Loehrer PJ, Propert K, et al. Long-term follow up of phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564- 9.
9. Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987: 60: 574- 85.
10. Miller AB, Hoogstaten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207- 14.
11. Sengelov L, Nielsen OS, Kamby C, von der Maase H. Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors. Cancer 1995; 76: 1747- 803.
12. Harker WG, Meyers FJ, Freiha FS, et al. Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A northern California oncology group study. J Clin Oncol 1985; 3: 1463- 70.
13. Geertsen PF, Sengelov L, Larsen SK, von der Maase H. A phase II study of cisplatin plus methotrexate with folonic acid rescue in metastatic or locally recurrent transitional cell carcinoma of the urothelium. Eur J Cancer 1993; 29A: 347- 50.
14. Hillcoat BL, Raghavan D, Matthews J, et al. A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 1989; 7: 706- 9.
15. Allegra JC, Woodcock T, Woolf S, et al. A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 1985; 3: 153- 61.
16. Bennett JM, Byrne P, Desai A, et al. A randomized multicenter trial of cyclophosphamide, novantrone and 5-fluorouracil (CNF) versus cyclophosfamide, adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Invest New Drugs 1985; 3: 179- 85.
17. Atiba JO, Green SJ, Hynes HE, Osborne CK, Miller TP, Davidner M. Phase II evaluation of mitoxantrone plus cisplatinum in patients with advanced breast cancer. Invest New Drugs 1994; 12: 129- 32.
18. Posner LE, Dukart G, Goldberg J, Bernstein T, Canwright K. Mitoxantrone: an overview of safety and loxicity. Invest New Drugs 1985; 3: 123- 32.
19. Mouridsen HT, Cornbleet M, Stuart-Harris R, et al. Mitoxantrone as first-line chemotherapy in advanced breast cancer; results of a collaborative European study. Invest New Drugs 1985; 3: 139- 48.
20. Sridhar KS, Hussein AM, Benedetto P, et al. Phase II trial of mitoxantrone in head and neck Carcinoma. Am J Clin Oncol 1991; 14: 298- 304.
21. Roth BJ. Chemotherapy for advanced bladder cancer. Semin Oncol 1996; 23: 633- 44.